Further, glucagon-like peptide-1 receptor agonists (GLP-1RAs), including both short-acting (e.g., exenatide) and long-acting (e.g., liraglutide, semaglutide) formulations, are emerging as effective therapies for MASLD and MASH. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.